Novavax Inc. (NVAX)
Novavax Q3 Earnings & Sales Beat, Stock Falls 6% on '24 View Cut
NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, citing lower COVID-19 vaccine uptake.
Novavax Q3 Earnings Disappoint, But A Turnaround May Be Underway
Novavax reported a net loss of $0.76/share and $84.5M in revenue, beating estimates but cutting guidance due to lower COVID-19 vaccine sales. Revenue has declined since 2022, prompting a substantial cost reduction program set to refocus the company on 4 key value drivers. A collaboration with Sanofi offers flexibility and potential growth, allowing Novavax to focus on developing a COVID-19/influenza combination (CIC) and seasonal influenza vaccines.
NVAX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Novavax, Inc.
NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novavax, Inc. ("Novavax, Inc.") (NASDAQ:NVAX) concerning possible violations of federal securities laws. On October 16, 2024, NVAX announced the Food and Drug Administration placed a clinical hold on the development of the company's combination influenza and Covid-19 (CIC) shot and its stand-alone influenza vaccine.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX
NEW YORK CITY, NY / ACCESSWIRE / November 12, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ:NVAX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Novavax, Inc. (NVAX) Q3 2024 Earnings Call Transcript
Novavax, Inc. (NASDAQ:NVAX ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Luis Sanay - Vice President, Investor Relations John Jacobs - President and Chief Executive Officer John Trizzino - President and Chief Operating Officer Robert Walker - Senior Vice President and Chief Medical Officer Jim Kelly - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants Roger Song - Jefferies Mayank Mamtani - B. Riley Securities Eric Joseph - JPMorgan Vernon Bernardino - H.C.
Novavax Stock is Slipping After the Vaccine Maker Cut its Outlook Again
Novavax (NVAX) shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results.
Novavax's stock slides 7% as guidance cut offsets narrower-than-expected third-quarter loss
Novavax Inc.'s stock fell 4% Tuesday after the company cut its full-year guidance, offsetting a narrower-than-expected third-quarter loss and better-than-expected revenue.
Novavax (NVAX) Reports Q3 Loss, Tops Revenue Estimates
Novavax (NVAX) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to loss of $1.26 per share a year ago.
Novavax Stock Dives Even Though Results Beat Forecasts
The vaccine maker posted a narrower third-quarter loss than expected at 76 cents a share. Revenue was $85 million, compared with the $74 million analysts expected.
Lost Money on Novavax, Inc. (NVAX)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novavax, Inc. ("Novavax, Inc.") (NASDAQ:NVAX) concerning possible violations of federal securities laws. On October 16, 2024, NVAX announced the Food and Drug Administration placed a clinical hold on the development of the company's combination influenza and Covid-19 (CIC) shot and its stand-alone influenza vaccine.
Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales
Novavax cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell the shot to Sanofi.
Novavax Gets FDA Approval To Resume Testing Two Vaccines After Clinical Hold
Novavax (NVAX) shares edged higher Monday after the drugmaker announced that federal regulators have given the company the go-ahead to continue testing its combination COVID-19-flu and standalone flu vaccines.
